The global mucinoses management market is expected to reach a valuation of US$ 112.81 million in 2023 and is projected to exhibit a CAGR of 19.5% from 2023 to 2033, reaching US$ 669.95 million.
The mucinoses management market is projected to expand as a result of numerous variables influencing the healthcare industry, such as greater government investment in studies and development, along with substantial changes implemented into the system to allow numerous medical professionals to focus not solely on providing adequate quantity is handled, but also on ensuring the level of service is not undermined by medical providers. In 2017, the EU's government spending on healthcare was documented at US$ 1,221 million, accounting for approximately 7.1% of GDP.
An increase in the volume of studies and development associated with topical corticosteroids by market participants is anticipated to aid in expanding topical corticosteroids by market participants is anticipated to aid in the expansion of the topical corticosteroids (steroids) segment over the projected timeframe, contributing to the industry's development. For instance, in April 2022, the global pharmaceutical company Eli Lilly and Company declared that Lebrikizumab, an IL-13 inhibitor, drastically enhanced treatment response when merged with topical corticosteroids (TCS) in individuals with mild-to-severe atopic dermatitis (AD) in the 3rd pivotal Phase 3 trial (ADhere). Moreover, the growing cases of skin-related illnesses, such as skin irritation, dermatitis, itchiness, eczema, and psoriasis, have contributed to the growth of the corticosteroid injections segment, which will push market growth even further.
SHJCM (self-healing juvenile cutaneous mucinosis) is a rare condition with fewer than 20 reported incidents globally. Based on the rarediseaseday.org February 2022 update, approximately 300 million individuals around the world live with rare diseases, which is an incredibly large number. As a result, the requirement for efficient and sophisticated treatment methods for rare conditions is predicted to rise. due to the substantial liability and heightened awareness about such diseases, which is anticipated to drive growth in the researched market during the forecast period.
The increased incidences of head and neck cancer will be a prime motivator factor for the expansion of the North American drastic oral mucositis market over the coming years. The major players in the United States are concentrating on raising funds to augment studies and development for treating chronic oral mucositis in cancer sufferers caused by radiation therapy and chemotherapy. Thus, owing to this factor North America is expected to witness market growth. The expansion of Asia Pacific can be credited to government schemes to assist orphan illness patients. For instance, the Indian government oriented federal and state governments in July 2022 to make sure that the implementation of healthcare programs evolved to treat patients experiencing orphan diseases. As a result, this aspect will have an impact on the Asia Pacific mucinoses management market over the upcoming decades.
In the midst of global challenges, market participants have begun to seek safe investments by concentrating on emerging technology and product releases. As the US government stands focused on quality by stimulating demand for Medicaid and Medicare, federal subsidies to medical equipment, pharmaceutical, and biotech companies will profit market participants in both short and long-term goals. In 2021, the United States spent $12,318 per individual on health coverage, the most of any OECD country, preceded by Germany at $7,383. The federal government's approach to healthcare systems will allow market makers to increase their earnings while minimizing the threat posed by inflation, resulting in market growth.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 112.81 Million |
| Anticipated Forecast Value (2033) | US$ 669.95 Million |
| Projected Growth Rate (2023 to 2033) | 19.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The coronavirus (COVID-19) pandemic and shutdown in different parts of the world have had an economic effect on corporations of all sizes. The COVID-19 pandemic has had a substantial effect on the private medical industry. Furthermore, the coronavirus pandemic has had an adverse effect on the development, manufacturing, and delivery of pharmaceutical drugs, along with the expansion of many oral mucositis medication firms around the world. From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 18%.
However, now, that the industries are getting back to their normal functioning, the global demand for mucinoses management market is projected to increase at a CAGR of 19.5% during the forecast period between 2023 and 2033, reaching a total of US$ 669.95 Million in 2033, according to a report from Future Market Insights (FMI).
A Rich Investment Landscape Facilitated by the Presence of Key Market Players driving Growth
The key participants are concentrating on investment initiatives in order to enhance studies and innovations for the treatment of serious oral mucositis in cancer survivors prompted by radiation and chemotherapy. Galera Therapeutics, Inc., for instance, revealed in September 2018 that it had assured US$ 150 million in a combined, received Series C financing and royalty purchase agreement.
Clarus directed the funding, which was co-led by Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital, and Tekla Capital Management LLC. Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures, and Sofinnova Ventures were among the bondholders who took part.
Multiple and Innovative Expansion Strategies drive Market Growth
A comprehensive strategy based on breakthrough initiatives for the development of novel SMA medicines to address unmet medical needs in rare disease therapeutics is predicted to propel industry growth.
In June 2021, for instance, the European expert group on orphan drug incentives released a package of policy initiatives to address unmet healthcare needs in rare conditions. This proposed policy involves a modification of the EMA's pharma strategy and orphan drug laws in order to encourage Capital investments in orphan drugs. As a result, this factor is expected to fuel market growth.
Principal Consultant
High Costs may hinder Market Growth
The high additional cost related to severe mucositis in cancer patients is one of the main factors impeding overall growth. Based on a 2019 study published by Oxford University Press, patients receiving chemotherapy and radiation therapy for the diagnosis of head and neck cancers must incur an additional expense for the treatment of side effects such as serious mucositis.
As per the same source, patients must pay an additional US$ 5,000-30,000 for the treatment of mucositis resulting from radiation therapy, while patients must pay an extra US$ 3,700 per loop for oral mucositis caused by chemotherapeutics in the United States.
Increased Prevalence of Cancer to drive the adoption of Mucinoses Management
The increased incidence of head and neck cancer area major driver of the North American mucositis management market in the coming years. Based on the American Society of Clinical Oncology's (ASCO) 2021 survey, roughly 4% of people in the United States had head and neck cancer, with an estimated 66,630 people (48,740 men and 17,890 women) developing the disease.
The region's increasing geriatric population (aged 65 and up) is also a significant contributor to the industry's growth. According to Statista's most recent report, from 2011 to 2021, 17.04 percent of the people in the United States wereover the age of 65. The severe oral mucositis market in the United States wasexpected to be worth US$ 79 million in 2021.
The Asia Pacific mucositis management market is anticipated to expand due to the various opportunities provided by the region's governments' soaring healthcare spending. For example, as per World Bank data, existing health expenditure per capita in Japan increased from US$2,754.38 in 2006 to US$ 4,360.47 in 2019. Healthcarespending as a percentage of national GDP obtained 10.74% in 2019, up from 7.69% in 2006.
Furthermore, Asia Pacific is predicted to be the fastest-growing region in the treatment of rare diseases. The region's expansion can be credited to government schemes to assist orphan disorder patients. For instance, the Indian government directed the federal and state governments in July 2022 to make sure that the implementation of healthcare programs wasestablished to treat patients experiencing orphan diseases. This assessment allows companies to provide high-quality orphan drugs to the administration while also total revenues. As a result, this aspect will contribute to industry growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Eczema and Atopic DermatitispropelTopical Corticosteroids Segment Growth
Over the forthcoming years, the growing number of studies and developments associated withtopical corticosteroids by market participants is anticipated to aid in the expansion of the topical corticosteroids (steroids) industry. Eczema and atopic dermatitis are predicted to drive thetopical corticosteroids segment's growth in themarket.
Key players in the Mucinoses Management market are Gsk plc, Almirall, S.A, Merck & Co., Inc, Bausch Health, Sandoz International GmbH, Pfizer Inc, AstraZeneca, Sanofi, Alencure Biotech, Divine Laboratories. Some of the latest developments by key manufacturers are below
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 112.81 Million |
| Market Value in 2033 | US$ 669.95 Million |
| Growth Rate | CAGR of 19.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market is valued to hit US$ 669.95 million by 2033.
The market is forecast to register a CAGR of 19.5% through 2033.
The market is estimated to secure a valuation of US$ 112.81 million in 2023.
During 2018 to 2022, the market evolved at a CAGR of 18%.
A thriving investment environment made possible by the presence of significant market players fostering growth.
Considerable additional expense associated with severe mucositis in cancer patients.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Topical Corticosteroids
5.3.2. Corticosteroid Injections
5.3.3. Oral Antibiotics
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Intralesional
6.3.3. Topical
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East & Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Class
14.1.2.2. By Route of Administration
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Class
14.2.2.2. By Route of Administration
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Class
14.3.2.2. By Route of Administration
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Class
14.4.2.2. By Route of Administration
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Class
14.5.2.2. By Route of Administration
14.5.2.3. By Distribution Channel
14.6. United kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Class
14.6.2.2. By Route of Administration
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Class
14.7.2.2. By Route of Administration
14.7.2.3. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Class
14.8.2.2. By Route of Administration
14.8.2.3. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Class
14.9.2.2. By Route of Administration
14.9.2.3. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Class
14.10.2.2. By Route of Administration
14.10.2.3. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Class
14.11.2.2. By Route of Administration
14.11.2.3. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Class
14.12.2.2. By Route of Administration
14.12.2.3. By Distribution Channel
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Class
14.13.2.2. By Route of Administration
14.13.2.3. By Distribution Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Class
14.14.2.2. By Route of Administration
14.14.2.3. By Distribution Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Class
14.15.2.2. By Route of Administration
14.15.2.3. By Distribution Channel
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Class
14.16.2.2. By Route of Administration
14.16.2.3. By Distribution Channel
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Class
14.17.2.2. By Route of Administration
14.17.2.3. By Distribution Channel
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Class
14.18.2.2. By Route of Administration
14.18.2.3. By Distribution Channel
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Class
14.19.2.2. By Route of Administration
14.19.2.3. By Distribution Channel
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Class
14.20.2.2. By Route of Administration
14.20.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. GSK Plc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Almirall, S.A
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Merck & Co., Inc.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Bausch Health
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Sandoz International GmbH
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Pfizer Inc.
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. AstraZeneca
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Sanofi
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Alencure Biotech
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Divine Laboratories
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Mucinoses Management Market
